ImmunityBio, Inc.
NASDAQ:IBRXBiotechnology
Healthcare
$6.57 +2.58%
+$0.18 today
- Market cap
- $6.99B
- Beta
- 0.10
- P/E (TTM)
- -8.6
- EPS (TTM)
- -$0.83
52W Low $1.95High $12.43
Volume 11.10M
Average 16.40M
Income Statement
Follow revenue through to earnings.
Revenue
$113.29M
FY 2025 · Annual
+668.3% YoYOperating Income
-$256.03M
FY 2025 · Annual
Net Income
-$351.40M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 934K | 240K | 622K | 14.75M | 113.29M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 753K |
| Gross Profit | 934K | 240K | 622K | 14.75M | 112.54M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 99.3% |
| Research & Development | 195.96M | 248.15M | 232.37M | 190.14M | 207.88M |
| Selling, General & Admin | 135.26M | 102.71M | 129.62M | 168.78M | 147.18M |
| Operating Expenses | 331.21M | 351.54M | 362.87M | 358.93M | 368.56M |
| Depreciation & Amortization | 14.24M | 18.26M | 18.51M | 17.55M | 15.53M |
| EBITDA | (320.75M) | (351.88M) | (478.66M) | (264.43M) | (223.56M) |
| EBITDA Margin | -34341.8% | -146617.1% | -76955.5% | -1793.4% | -197.3% |
| Operating Income | (330.28M) | (351.3M) | (362.25M) | (344.18M) | (256.03M) |
| Operating Margin | -35361.9% | -146374.2% | -58239.5% | -2334.2% | -226.0% |
| Interest Income | 836K | 2.71M | 863K | 2.4M | 6.7M |
| Interest Expense | 14.85M | 47.15M | 86.72M | 131.66M | 112.53M |
| Other Income / Expenses | (19.56M) | (65.99M) | (221.64M) | (69.46M) | (95.58M) |
| Income Before Tax | (349.84M) | (417.29M) | (583.89M) | (413.65M) | (351.61M) |
| Pre-Tax Margin | -37456.0% | -173869.2% | -93873.3% | -2805.3% | -310.4% |
| Income Tax Expense | 9K | 34K | (40K) | 0 | (135K) |
| Net Income | (346.79M) | (416.57M) | (583.2M) | (413.56M) | (351.4M) |
| Net Margin | -37129.6% | -173569.6% | -93761.4% | -2804.8% | -310.2% |
| EPS (Basic) | (0.89) | (1.04) | (1.15) | (0.59) | (0.38) |
| EPS (Diluted) | (0.89) | (1.04) | (1.15) | (0.62) | (0.38) |
| 389.23M | 399.9M | 508.64M | 697.31M | 919.86M | |
| 389.23M | 399.9M | 508.64M | 700.44M | 919.86M |
IBRX Earnings Waterfall · TTM
NASDAQ:IBRX · Revenue to Net Income
Key Ratios
EPS$-1.08
Gross Margin96.3%
Net Margin-605.2%
P/E Ratio-8.7
P/S Ratio153.4
Analysis
$182.6M of revenue converted into -$1.1B of net income for the selected period. Gross margin is 96.3% and net margin is -605.2%, showing how much revenue survives after costs and taxes. EPS is $-1.08, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 9, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| 8-K | Current report | Oct 14, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 6, 2026 |
How much revenue does IBRX generate?
ImmunityBio, Inc. (IBRX) reported $113.29M of revenue in fiscal 2025.
Is IBRX profitable?
ImmunityBio, Inc. (IBRX) reported -$351.40M of net income, with a net margin of -310.2%.
Continue the stock analysis
Jump to another research area for this company.